Syndax Pharmaceuticals Stock Current Valuation
| 1T3 Stock | EUR 12.80 0.10 0.78% |
Valuation analysis of Syndax Pharmaceuticals helps investors to measure Syndax Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Syndax Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Syndax Pharmaceuticals is based on 3 months time horizon. Increasing Syndax Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Syndax stock is determined by what a typical buyer is willing to pay for full or partial control of Syndax Pharmaceuticals. Since Syndax Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Syndax Stock. However, Syndax Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.8 | Real 10.75 | Hype 12.8 |
The real value of Syndax Stock, also known as its intrinsic value, is the underlying worth of Syndax Pharmaceuticals Company, which is reflected in its stock price. It is based on Syndax Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Syndax Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Syndax Pharmaceuticals helps investors to forecast how Syndax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Syndax Pharmaceuticals more accurately as focusing exclusively on Syndax Pharmaceuticals' fundamentals will not take into account other important factors: Syndax Pharmaceuticals Company Current Valuation Analysis
Syndax Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Syndax Pharmaceuticals Current Valuation | 979.72 M |
Most of Syndax Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Syndax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Syndax Pharmaceuticals has a Current Valuation of 979.72 M. This is 93.18% lower than that of the Healthcare sector and 78.91% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 94.11% higher than that of the company.
Syndax Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Syndax Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Syndax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics of similar companies.Syndax Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Syndax Fundamentals
| Return On Equity | -0.0519 | |||
| Return On Asset | -0.0292 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | (0.11) % | |||
| Current Valuation | 979.72 M | |||
| Shares Outstanding | 68.1 M | |||
| Shares Owned By Insiders | 4.22 % | |||
| Shares Owned By Institutions | 95.78 % | |||
| Price To Book | 4.08 X | |||
| Price To Sales | 12.70 X | |||
| Revenue | 139.71 M | |||
| Gross Profit | 139.71 M | |||
| EBITDA | 26.22 M | |||
| Net Income | 24.93 M | |||
| Cash And Equivalents | 95.37 M | |||
| Cash Per Share | 3.52 X | |||
| Total Debt | 19.89 M | |||
| Debt To Equity | 1.90 % | |||
| Current Ratio | 6.24 X | |||
| Book Value Per Share | 5.62 X | |||
| Cash Flow From Operations | 29.13 M | |||
| Target Price | 27.67 | |||
| Number Of Employees | 59 | |||
| Beta | 1.06 | |||
| Market Capitalization | 1.67 B | |||
| Total Asset | 449.66 M | |||
| Z Score | 49.8 | |||
| Net Asset | 449.66 M |
About Syndax Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Syndax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Syndax Stock
When determining whether Syndax Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Syndax Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Syndax Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Syndax Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.